Published in Diabetes Technol Ther on June 20, 2013
A real-world study of the effect of timing of insulin initiation on outcomes in older medicare beneficiaries with type 2 diabetes mellitus. J Am Geriatr Soc (2015) 1.45
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol (2015) 0.95
Pancreatic β-cell identity in diabetes. Diabetes Obes Metab (2016) 0.79
Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis. Diabetes Ther (2015) 0.78
Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. Vasc Health Risk Manag (2015) 0.75
Renal protective effects of Porphyra dentate aqueous extract in diabetic mice. Biomedicine (Taipei) (2014) 0.75
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. Diabetes Ther (2017) 0.75
Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes. Adv Ther (2015) 0.75
Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations. Diabetes Ther (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med (2007) 8.31
Pancreatic Extracts in the Treatment of Diabetes Mellitus. Can Med Assoc J (1922) 7.97
Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med (2009) 7.08
Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care (2005) 3.55
Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care (2000) 3.35
Vital signs: prevalence, treatment, and control of hypertension--United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep (2011) 3.31
Progression of incipient diabetic retinopathy during good glycemic control. Diabetes (1987) 3.30
The burden of treatment failure in type 2 diabetes. Diabetes Care (2004) 3.14
The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes (1985) 2.46
Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care (2004) 2.46
Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab (2008) 2.21
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care (1997) 1.99
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care (2004) 1.97
Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes (2005) 1.84
Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. MMWR Morb Mortal Wkly Rep (2011) 1.84
β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care (2012) 1.66
Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl (2009) 1.63
A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care (2006) 1.59
Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care (2008) 1.54
Latent autoimmune diabetes in adults (LADA): usefulness of anti-GAD antibody titers and benefit of early insulinization. Arq Bras Endocrinol Metabol (2007) 1.40
Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care (2003) 1.38
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care (2009) 1.38
Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J (1976) 1.28
Insulin enhances glucose-stimulated insulin secretion in healthy humans. Proc Natl Acad Sci U S A (2010) 1.25
Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol (2006) 1.23
Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab (2007) 1.13
Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin. Indian J Endocrinol Metab (2012) 1.13
Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care (2011) 1.11
Insulin infusion in acute illness. J Clin Invest (2005) 1.10
Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care (2007) 1.10
Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract (2007) 1.06
Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev (2003) 0.97
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab (2011) 0.97
Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet (2008) 0.96
Type 1 1/2 diabetes: myth or reality? Autoimmunity (1999) 0.93
Enhanced expression of insulin receptor substrate-2 and activation of protein kinase B/Akt in regenerating pancreatic duct epithelium of 60 %-partial pancreatectomy rats. Diabetologia (2001) 0.92
The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. Diabetes Obes Metab (2011) 0.92
Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care (2011) 0.89
Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol (2013) 0.89
β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol (2010) 0.89
The effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients. Korean J Intern Med (2010) 0.88
Further Clinical Experience with Insulin (Pancreatic Extracts) in the Treatment of Diabetes Mellitus. Br Med J (1923) 0.86
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care (2013) 0.85
Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. Diabetes Technol Ther (2011) 0.81
Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract (2010) 0.80
Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. Diabetes Technol Ther (2008) 0.78